[摘要] 目的 探讨硼替佐米联合地塞米松治疗多发性骨髓瘤的临床疗效。方法 便利选取2016年2月—2017年2月期间该院80例多发性骨髓瘤患者，根据随机数字法，将其分为对照组(常规化疗)和观察组(硼替佐米联合地塞米松化疗)，每组各40例，比较两组临床疗效，化疗前后骨痛程度、血钙、血磷水平变化情况，以及化疗期间不良反应。 结果 与对照组相比，观察组总有效率明显增高(92.5% vs 55.0%，P<0.05)；与对照组相比，观察组患者化疗后骨痛程度，血钙、血磷水平均显著降低，差异有统计学意义(P<0.05)；两组都没有出现严重不良反应。 结论 硼替佐米联合地塞米松能够明显提高多发性骨髓瘤的临床疗效，为治疗提供新的治疗方向。

    [关键词] 硼替佐米；地塞米松；多发性骨髓瘤

    [中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2017)11(b)-0133-03

    [Abstract] Objective This paper tries to study the clinical efficacy of bortezomib combined with dexamethasone in the treatment of multiple myeloma. Methods Convenient selected 80 patients with multiple myeloma in this hospital from February 2016 to February 2017 were randomized into the control group (with routine chemotherapy) and the observation group (with bortezomib and dexamethasone) according to the random number method. The clinical efficacy ......